Receipt date: 02/19/2010

Doc code: IDS

Doc cescription: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (01-10)

Approved for use through 07/31/2012. OMB 0651-007

mation Disclosure Statement (IDS) Filed

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		09830992	
	Filing Date		2001-05-03	
INFORMATION DISCLOSURE	First Named Inventor Lubiso		ibisch	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1626	
(Not for submission under 37 CFR 1.99)	Examiner Name	Stock	ton, Laura L.	
	Attorney Docket Number		0050/049500USO1	

				U.S.I	PATENTS	
Examiner Initial*	Cite No	Patent Number	Rind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	4093726	A	1970-06-06	Winn et al.	
	2	6372736	B1	2002-04-16	Kemp et al.	
	3	6696437	B1	2004-02-24	Lubisch et al.	
	4	7462724	B2	2008-12-09	Penning et al.	
	5	7550603	В	2008-06-23	Zhu et al.	
If you wis	h to add	additional U.S. Pater		·	ease click the Add button.	
,			U.S.P	ATENT APPLI	CATION PUBLICATIONS	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030100582	A1	2003-05-29	Sircar et al.	

Receipt date: 02/19/2010 **Application Number** 09830992 Filing Date 2001-05-03 INFORMATION DISCLOSURE First Named Inventor Lubisch STATEMENT BY APPLICANT Art Unit 1626 (Not for submission under 37 CFR 1.99) **Examiner Name** Stockton, Laura L. Attorney Docket Number 0050/049500USO1 20060229351 2 **A1** 2006-10-12 Zhu et al. 3 20070179136 Α1 2007-08-02 Penning et al. 2007-11-15 4 20070265324 Α1 Werner et al. 5 20090186877 Α1 2009-03-Giranda et al Α1 2008-07-15 Ga dhi et al. 6 20090030016 If you wish to add additional U.S. Published Application citation information please click the Add button. FOREIGN PATENT DOCUMENTS Pages, Columns, Lines Name of Patentee or Examiner Cite Foreign Document Country Kind Publication where Relevant Appricant of cited **T**5 Initial* No Number³ Code2 i Code4 Date Passages or Relevant Document Figures Appear Boehringer Manheim 3830060 Α1 1990-03-15 X 1 Gmbh 19916460 DE 2 Α1 2000-10-19 **BASF AG** X 19929936 3 DE **A1** 2001-11-09 **BASF AG** 10021468 DE Α1 2001-11-08 **BASF AG** X Receipt date: 02/19/2010 **Application Number** 09830992 Filing Date 2001-05-03 INFORMATION DISCLOSURE First Named Inventor Lubisch STATEMENT BY APPLICANT Art Unit 1626 (Not for submission under 37 CFR 1.99) **Examiner Name** Stockton, Laura L. Attorney Docket Number 0050/049500USO1 5 1354554 GB Α 1974-06-05 Robins Co Inc Univ Newcastle Vertures wo Α1 6 97/04771 1997-02-13 LTD Metabasis Therapeutics WO Α1 1998-09-11 7 98/39343 Inc 8 00/26192 WO 2000-05-11 **BASF AG** 9 00/29384 wo Α1 20 €0-05-25 **BASF AG** 2000-06-08 00/32579 WO **BASF AG** 10 Yaman uchi Pharma Co WO 2001-03-29 11 01/21615 **A1** X Ltd wo 12 01/21634 Α1 2001-03-29 Trega Biosciences 01/82877 WO 13 A2 2001-11-08 **BASF AG** If you wish to add additional Foreign Patent Document citation information please click the Add button **NON-PATENT LITERATURE DOCUMENTS** Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Examiner Cite (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), **T**5 Initials* publisher, city and/or country where published.

Receipt date: 02/19/2010

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09830992			
Filing Date		2001-05-03			
First Named Inventor Lubi		sch			
Art Unit		1626			
Examiner Name	Stoc	kton, Laura L.			
Attorney Docket Numb	oer	0050/049500USO1			

1	Gilchrist, e. al., "Cyclisation of ortho-Substituted N-Arylben zimidoyl Nitrenes. Part 2. Preferential Cyclisations at an ortho-Position Bearin a Methoxycarbonyl Group", Journal of Chem. Society, Perkin Transactions 1, GB, Chemical Society, Letch orth, 2303-2307 (1979)	
2	Griffin, et al., "Resistance modifying agents 3. Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribosa) polymerase." Pharmaceutical Sciences, 2(1), 43-47 (1996)	
3	Kröger, H., et al., "Synergistic Effects of Thalidomide and Poly(ADP-Ribose), olymerase Inhibition of Type II Collagen-Induced Arthritis in Mice", Inflammation, 20(2):203-215 (1996)	
4	Burkart, V., et al., "Mice lacking the poly (ASP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin" Nat. Med., 5(3):314-319 (1999)	
5	Chen, et al., "Potentiation of the antitumor activity of deplatin in mice by 3-aminobenzamide and nicotinamide", Cancer Chem. Pharm., 22:303-307 (1988)	
6	Cuzzocrea, S., et al., "Protective effects of 3 minobenzamide, an inhibitor of poly (ADP-ribose) synthase in a carrageenan-induced model of local inflammation", Eur. J. of Pharta., 342:67-76 (1998)	
7	Ehrlich, W., et al., "Inhibition of the induction of collagenase by interleukin- kin cultured rabbit synovial fibroblasts after treatment with the poly(ADP-ribose)-polymerase inhibitor 3-aminobenzamide. Rheumatol Int., 15:171-172 (1995)	
8	Szabo, C., et al., "Protection against peroxynitrite-induced fibroblast injury and arthritic development by inhibition of poly(ADP-ribose) synthase", Proc. Natl., Acad. Sci. USA, 95:3867-3872 (1998)	
9	Thiemermany, C., et al., "Inhibition of the activity of poly (ADP ribose) synthhetase reduces ischamia-reperfusion injury in the heart and skeletal muscle", Proc. Natl. Acad. Sci. USA, 94:679-683 (1997)	
10	Westin, D., et al., "Immunosuppressive Activities of 6(5H)-Phenanthridinone, A New Poly(ADP-Ribose)Polymerase Inhibitor", Int. J. Immunopharmac., 17(4):265-271 (1995)	
11	White, A.W., et al. "Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitor", Bioorganic & Medicinal Chemistry Letters, 2004, 14:2433-2437 (2004)	

eceipt date: 02/19/2010	Application Nu	mher	09830992			
	Filing Date	Application Number		2001-05-03		
INFORMATION DISCLOS	JRE First Named In	ventor I	ubisch			
STATEMENT BY APPLICA	ANT Art Unit			1626		
(Not for submission under 37 CFR	1.99) Examiner Nam	و ا	tockton, Laura L.	 		
	Attorney Docke					
	Theomey Books	- Number	0000/040000001			
		=				
12 Co-pending Application	U.S. Patent Application No.	11/401,635				
13 Co-pending Application	U.S. Patent Application No.	12/413,834				
14 Co-pending Application	U.S. Patent Application No.	11/623,996				
15 Co-pending Application	U.S. Patent Application No.	11/970,828				
16 Co-pending Application	U.S. Patent Application No.	12058,478				
17 Co-pending Application	U.S. Patent Application No.	12/116,823				
18 Co-pending Application	U.S. Patent Application No.	12/117,452				
19 Co-pending Application	U.S. Patent Application No.	12/173,213				
If you wish to add additional non-pater	nt literature document citat			utton		
Examiner Signature // // //		SIGNATO	Date Considered	T	04/04/0010	
*EXAMINER: Initial if reference consideration if not in conformance and not of			nformance with MPEP 609			
¹ See Kind Codes of USPTO Patent Documents Standard ST 36. ³ For Japanese patent docume ⁴ Kind of document by the appropriate symbols English language translation is attached.	ents, the indication of the year of	the reign of t	ne Emperor must precede the se	erial number o	of the patent docume	

S Web 2.1.17